Titre:
  • Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Auteur:Keymeulen, Bart; Vandemeulebroucke, Evy; Ziegler, Anette G; Mathieu, Chantal; Kaufman, Leonard; Hale, Geoff; Gorus, Frans; Goldman, Michel; Walter, Markus; Candon, Sophie; Schandené, Liliane; Crenier, Laurent; De Block, Christophe; Seigneurin, Jean-Marie; De Pauw, Pieter; Pierard, Denis; Weets, Ilse; Rebello, Peppy; Bird, Pru; Berrie, Eleanor; Frewin, Mark; Waldmann, Herman; Bach, Jean-François; Pipeleers, Daniel; Chatenoud, Lucienne
Informations sur la publication:The New England journal of medicine, 352, 25, page (2598-2608)
Statut de publication:Publié, 2005-06
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adolescent
Adult
Antigens, CD3 -- immunology
Autoantibodies -- blood
Blood Glucose -- analysis
C-Peptide -- biosynthesis
Child
Diabetes Mellitus, Type 1 -- blood
Diabetes Mellitus, Type 1 -- drug therapy
Diabetes Mellitus, Type 1 -- immunology
Female
Glucose Clamp Technique
Herpesviridae -- isolation & purification
Humans
Hypoglycemic Agents -- therapeutic use
Immunoglobulin G -- adverse effects
Immunoglobulin G -- therapeutic use
Insulin -- therapeutic use
Islets of Langerhans -- drug effects
Islets of Langerhans -- immunology
Islets of Langerhans -- physiopathology
Male
Note générale:Clinical Trial
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0028-4793
info:doi/10.1056/NEJMoa043980
info:pii/352/25/2598
info:scp/20544443927
info:pmid/15972866